Ritescribe Med Info Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 21 Year, 9 Days
- Last Filing with ROC 31 Mar 2019
- Open Charges ₹ 1.00 M
- Revenue Growth %
- Profit Growth -100.38%
- Ebitda 80.63%
- Net Worth -6.40%
- Total Assets -2.72%
About Ritescribe Med Info
Ritescribe Med Info Private Limited (RMIPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 January 2004 and has a history of 21 years. Its registered office is in Karwar 581 301, Karnataka.
The Company is engaged in the Printing & Publishing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.00 M.
Janardhan Tandel and Santosh Pitambar serve as directors at the Company.
Company Details
-
LocationKarwar 581 301, Karnataka
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74140KA2004PTC033235
-
Company No.
033235
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Jan 2004
-
Date of AGM
30 Sep 2019
-
Date of Balance Sheet
31 Mar 2019
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Ritescribe Med Info?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Janardhan Tandel
|
Director | 23-Jan-2004 | Current |
|
Santosh Pitambar
|
Whole-Time Director | 23-Jan-2004 | Current |
Financial Performance of Ritescribe Med Info.
Ritescribe Med Info Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 100.38% decrease in profit. The company's net worth dipped by a decrease of 6.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ritescribe Med Info?
In 2017, Ritescribe Med Info had a promoter holding of 10.00% and a public holding of 90.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 Feb 2010 | Others | ₹1.00 M | Open |
How Many Employees Work at Ritescribe Med Info?
Unlock and access historical data on people associated with Ritescribe Med Info, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ritescribe Med Info, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ritescribe Med Info's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.